Experience with cyclosporine

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S135-S138

  Ready, A ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; AZATHIOPRINE; CYCLOSPORIN A; PREDNISOLONE; STEROID;

BIOEQUIVALENCE; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MONITORING; DRUG SAFETY; GINGIVA HYPERPLASIA; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYDROPHOBICITY; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; KIDNEY DISEASE; MICROEMULSION; NEPHROTOXICITY; PREMATURITY; PRIORITY JOURNAL; REVIEW; SMALL FOR DATE INFANT; TREMOR;

EID: 1642312100     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2003.12.049     Document Type: Article

References (32)

1. Calne R.Y., White D.J., Thiru S., et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 2:1978;1323.
2. Kahan B.D., Van Buren C.T., Flechner S.M., et al. Clinical and experimental studies with cyclosporine in renal transplantation. Surgery. 97:1985;125.
3. Borel J.F., Feurer C., Gubler H.U., et al. Biological effects of cyclosporin A a new antilymphocytic agent. Agents Actions. 6:1976;468.
4. Johansson A., Moller E. Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. Transplantation. 50:1990;1001.
5. Henderson D.J., Naya I., Bundick R.V., et al. Comparison of the effects of FK506, cyclosporine A, and rapamycin on IL-2 production. Immunology. 73:1991;316.
6. Bennett W.M., DeMattos A., Meyer M.M., et al. Chronic cyclosporine nephropathy the Achilles' heel of immunosuppressive therapy. Kidney Int. 50:1996;1089.
7. Drewe T., Beelinger C., Kissel T. The absorption site of cyclosporine in the human gastrointestinal tract. Br J Clin Pharmacol. 33:1992;39.
8. Mehta M., Venkataramanan R., Burckart G.J., et al. Effect of bile on cyclosporine absorption in liver transplant patients. Br J Clin Pharmacol. 25:1988;579.
9. Tjia J.F., Webber I.R., Back D.J. CsA metabolism by the gastrointestinal mucosa. Br J Clin Pharmacol. 31:1991;344.
10. Flechner S.M., Kolbeinsson M.E., Tam J., et al. The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. Transplantation. 47:1989;806.
11. Goldstein D.J., Zuech N., Sehgal V., et al. Cyclosporine-associated end-stage nephropathy after cardiac transplantation incidence and progression. Transplantation. 63:1997;664.
12. Fisher N.C., Malag M., Gonzlez-Pinto I. The clinical impact of nephrotoxicity in liver transplantation. Transplantation. 69:(suppl 12):2000;SS18.
13. Kovarik J., Mueller E.A., van Bree J.B., et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation; a multicenter investigation in kidney transplant patients. Transplantation. 58:1994;658.
14. Kovarik J.M., Mueller E.A., van Bree J.B., et al. Reduced inter- and intra-individual variability in cyclosporine pharmacokinetics from a microemulsion formulation. Pharmacol Sci. 83:1994;444.
15. Mueller E.A., Kovarik J.M., van Bree J.B., et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res. 11:1994;301.
16. Niese D., Keown P. Safety and efficacy of microemulsion versus conventional cyclosporine in de novo renal allograft recipients. Kidney Int. 54:1998;938.
17. Pollard S.G., Lear P.A., Ready A.R., et al. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. Transplantation. 68:1999;1325.
18. Kahan B.D., Dunn J., Fitts C., et al. The Neoral formulation improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients. Transplant Proc. 26:1994;2940.
19. Grevel J., Welsh M.S., Kahan B.D. Cyclosporine monitoring in renal transplantation area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit. 11:1989;246.
20. Kahan B.D., Welsh M., Schoenberg L., et al. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation. 62:1996;599.
21. Keown P.A. New concepts in cyclosporine monitoring. Curr Opin Nephrol Hypertens. 11:2002;619.
22. Thervet E., Pfeffer P., Scolari M.P., et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation. 76:2003;903.
23. Flechner S.M. Minimizing calcineurin inhibitor drugs in renal transplantation. Transplant Proc. 35:(suppl 3):2003;S118.
24. Lorber M.I., Flechner S.M., Van Buren C.T., et al. Cyclosporine toxicity the effect of combined therapy using cyclosporine, azathioprine, and prednisone. Am J Kidney Dis. 9:1987;476.
25. Mourad G., Vela C., Ribstein J., et al. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. Transplantation. 65:1998;661.
26. Weir M.R., Anderson L., Fink J.C., et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation. 64:1997;1706.
27. Oberbauer R., Kreis H., Johnson R.W., et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients 2-year results of the Rapamune Maintenance Regimen Study. Transplantation. 76:2003;364.
28. Kahan B.D., Flechner S.M., Lorber M.I., et al. Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for from one to five years. Transplantation. 43:1987;197.
29. Armenti V.T., Moritz M.J., Davison J.M. Drug safety issues in pregnancy following transplantation and immunosuppression; effects and outcomes. Drug Saf. 19:1998;219.
30. Hou S. Pregnancy in chronic renal insufficiency and end-stage renal disease. Am J Kidney Dis. 33:1999;235.
31. Nyberg G., Haljamae U., Frisenette-Fich C., et al. Breast-feeding during treatment with cyclosporine. Transplantation. 65:1998;253.
32. Pollard S., Nashan B., Johnston A., et al. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Clin Ther. 25:2003;1654.